PPHM and Tarvacin discussion

"Fluffernutters who go everywhere looking to further their agenda's. Thye do it on every board. The science will speak for itself over time, and the time is coming. PL1"

Name-calling.

You failed to address the issue. That's because YOU are the one with the agenda.

You post like a nutcase on every board in the universe trying to encourage others to invest money on this company for science they don't even own.

Vertex had good news today. Look at the patents they own compared to Peregrine's:

Peregrine: http://tinyurl.com/79ut8
Vertex: http://tinyurl.com/78css

Also compare Vertex's chart with Peregrine's since they began trials (PPHM began Aug 8) and with the NASDAQ Index:

http://tinyurl.com/8ejoz

The assignee on the patent is the owner of the patent.

None of those list Peregrine Pharmaceuticals, the company you are invested in and the company that you're encouraging others to invest in as the assignee.

Fool.

[Preciouslife1]

backing their trials. I have NEVER asked or told anyone to buy shares in PPHM or any other company. That is a bold faced lie. I try to present the science and the economics behind the company. You are here just to start trouble and like all other boards, which this was free from for awhile, there comes in people like you trying to ruin something that was informing others of current events in PPHM. I will still present the information and science that is factual and backed up with news releases and PR's. You have a bad agenda and there is plenty of cyberspace in Yahoo that you can occupy.....

"Vertex is a different company with partners backing their trials. I have NEVER asked or told anyone to buy shares in PPHM or any other company. That is a bold faced lie. I try to present the science and the economics behind the company. You are here just to start trouble and like all other boards, which this was free from for awhile, there comes in people like you trying to ruin something that was informing others of current events in PPHM. I will still present the information and science that is factual and backed up with news releases and PR's. You have a bad agenda and there is plenty of cyberspace in Yahoo that you can occupy....."

Why do you think it is that Vertex has partners and Peregrine does not (after years of trying)?

I suggest that if you want to be completely honest that you post the fact that Peregrine doesn't even own the technology that you're touting.

;-)

[Preciouslife1]

Peregrine Pharmaceuticals is developing a version of 3G4 called Tarvacin for cancer treatment and recently received approval from the Food and Drug Administration for a phase I clinical trial. The compound was discovered by Dr. Thorpe's lab, and Peregrine has a sponsored research agreement with UT Southwestern to further develop the drug.

PPHM Management has reiterated many times during CC's and SHM that they want to take Tarvacin and Cotara through trials on their own so that they could fully maximize the value that successful trials will unlock on a myriad of indications. They don't want to sell out any share of this platform until they have to and then license and collaborate with with big pharma or big biotech. The information is in the SHM and CC scripts that are available here and on Peregrine's web site.
End of story.

[Preciouslife1]

New update on VRTX:
UPDATE 3-Vertex hepatitis C drug effective in small study
1:25 p.m. 01/09/2006
further CEO comment

By Bill Berkrot

NEW YORK, Jan 9 (Reuters) - Vertex Pharmaceuticals Inc. (VRTX) on Monday said a small study showed its experimental hepatitis C drug, in combination with a common treatment, proved significantly better than either medicine alone in reducing levels of the virus in the blood.

Following release of the data, Prudential raised its price target on Vertex shares to $37 from $28, helping to push them nearly 9 percent higher to a multi-year high.

The biotechnology company said six of eight patients who received its VX-950 protease inhibitor in combination with pegylated interferon reached a level of the hepatitis C virus that was too small to measure after just 14 days.

By comparison, only one of eight patients who received the Vertex drug alone achieved an undetectable level of the virus in that time, while none of the four patients taking the interferon drug alone did so.

The company said it expected to begin a three-month, mid-stage trial of the drug combination involving more than 200 patients in the next few months.

Hepatitis C, which affects more than 3 million people in the United States, significantly raises the risk for developing chronic liver disease, cirrhosis, cancer or the need for a liver transplant.

"These data show that VX-950 in combination with pegylated interferon produced a very rapid viral response in each of these patients, who are historically the most difficult to treat effectively," Dr. Henk Reesink, the study's lead investigator, said in a statement.

Current two-drug treatments for hepatitis C often must be taken for three months before half the patients reach undetectable levels of the virus, Vertex said.

The early-stage clinical trial involved 20 patients with the hardest-to-treat genotype 1 strain of the liver disease.

The eight patients in the combination arm received 750 milligrams of VX-950 in pill form every eight hours along with the standard dose of Roche Holding AG's pegylated interferon drug, Pegasys.

Pegylated interferon is interferon encased in a fat molecule called polyethylene glycol, which slows the ********************bolizing of the drug in the body and allows for less frequent dosing.

No VX-950 patients in the study reported serious adverse side effects, Vertex said.

"The data announced today provide further support for VX-950's potential to transform the standard of care in hepatitis C virus," Vertex Chief Executive Joshua Boger said.

The Vertex drug alone eradicated 99.99 percent of the virus in the blood, while the combination reduced viral levels by 99.9997 percent, the Cambridge, Massachusetts-based company said.

"That sounds like the same number, but when you're trying to wipe out a virus every nine is tough to get," Boger said.

In a television interview on Monday, Boger called the results "astounding and unprecedented."

Pegasys alone reduced the virus by 90 percent in the study.

In an earlier study of VX-950 alone, half of the patients taking the drug tested negative for the virus after 14 days, although the virus returned to detectable levels in five patients a month after the study concluded.

"If you go after the virus with two different mechanisms, you are much more likely to wipe it out," Boger said.

Vertex shares were up $2.79, or 8.9 percent, to $34.07 on Nasdaq, a level not seen since September of 2001.

Note the reduced effect when testing with the drug alone!!
What do you think will happen with PPHM shares if Tarvacin shows to work great as a stand alone treatment and as combo.

[Preciouslife1]

FYI..Idenix Pharmaceuticals Reports Positive 4-Week Data From A Phase IIb Clinical Trial Evaluating Valopicitabine (NM283) Combined with Pegylated Interferon in Treatment-Naive Hepatitis C Patients
08:03 a.m. 01/09/2006 Provided by


SAN FRANCISCO, Jan 09, 2006 /PRNewswire-FirstCall via COMTEX/ -- Idenix Pharmaceuticals, Inc. (IDIX) announced partial 4-week data today from an ongoing phase IIb clinical trial demonstrating that treatment with valopicitabine combined with pegylated interferon resulted in rapid and marked reduction in virus levels in treatment-nave genotype 1 hepatitis C patients. The mean reduction in virus levels was greater than or equal to 4 log10, or 99.99 percent, after 4 weeks of treatment among patients in the two dose groups that began on Day 1 with 800 mg doses of valopicitabine. This trial is almost fully enrolled, with a target enrollment of 175 patients at more than 20 medical centers in the U.S. These partial data will be presented at the 24th Annual JP Morgan Healthcare Conference on Wednesday, January 11 at 2:00 p.m. (PST).

"We are quite encouraged by the virologic responses demonstrated to date with these four-week data and believe that valopicitabine combined with pegylated interferon has the potential to substantially improve treatment efficacy compared to current therapy for chronic hepatitis C patients," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "We look forward to presenting additional data from this phase IIb clinical trial in the spring and initiating a phase III clinical trial in this patient population in the second half of 2006."

This ongoing 48-week phase IIb clinical trial in treatment-nave patients includes the following five randomized treatment arms, all involving dosing regimens of valopicitabine, administered once-daily, in combination with pegylated interferon alfa-2a (Pegasys(R)) 180 g per week: (A) pegylated interferon beginning on Day 8 plus valopicitabine ramping from 400 mg to 800 mg beginning at Day 29; (B) valopicitabine 200 mg beginning on Day 1 plus pegylated interferon beginning on Day 8; (C) valopicitabine ramping from 400 mg to 800 mg beginning on Day 1 plus pegylated interferon beginning on Day 8; (D) valopicitabine 800 mg beginning on Day 1 plus pegylated interferon beginning on Day 8; and (E) valopicitabine 800 mg plus pegylated interferon, both beginning on Day 1.

The partial 4-week data demonstrated that the four treatment arms that included valopicitabine in combination with pegylated interferon during the first four weeks (arms B-E) all produced proportionally greater suppression of serum HCV RNA as compared to the arm that included pegylated interferon alone for the first four weeks (arm A). At Week 4, mean HCV RNA reductions were 4.00 log10, 4.17 log10, 3.50 log10 and 3.09 log10, respectively, for arm E (15 patients), arm D (14 patients), arm C (18 patients) and arm B (17 patients). In comparison, patients in the arm receiving pegylated interferon alone for the first 4 weeks (arm A, 19 patients) achieved a mean HCV RNA reduction of 2.00 log10 . The mean HCV RNA reduction for the two 800 mg dose valopicitabine arms (arms D and E) was significantly greater than that of the pegylated interferon alone arm (arm A) (p<0.01). The addition of 800 mg of valopicitabine to pegylated interferon (arm D) led to viral clearance (PCR- negativity) in 50 percent of patients, compared to 11 percent in arm A, at Week 4.

Rapid virologic response (RVR), or a greater than or equal to 2 log10 reduction in viral load by Week 4, was achieved in 93 percent of patients in the two 800 mg dose valopicitabine arms (arms D and E), indicative of a degree of virologic response which, in treatment nave patients, is thought to correlate with potentially sustained viral clearance post treatment.

Preliminary data from the first 4 weeks of treatment indicate valopicitabine continues to demonstrate adequate tolerability when administered in combination with pegylated interferon. Of the 150 patients enrolled in the trial to date,**** ten patients discontinued treatment by week four; nine discontinuations were due to adverse events (including 1 SAE of severe dehydration), and one for logistical reasons. ********

Peg-INF has many side effects that I have posted here before. If Tarvacin can show comparable efficacy and safety data without the INF side effects that will be major boon for 3G4 platform. Next up is follow up trial and Tarvacin/Ribavirin combo trial. PL1

"Peregrine Pharmaceuticals is developing a version of 3G4 called Tarvacin for cancer treatment and recently received approval from the Food and Drug Administration for a phase I clinical trial. The compound was discovered by Dr. Thorpe's lab, and Peregrine has a sponsored research agreement with UT Southwestern to further develop the drug."

That's what I said.

You claimed that Peregrine OWNS the tech. They do not.

Call Peregrine Investor Relations. Ask if they OWN those patents you claimed they own. They will tell you they do not own them. Because they don't.

Real biotech's (and real companies) actually own what they're selling/developing.

Duh.

[Preciouslife1]

+++Real biotech's (and real companies) actually own what they're selling/developing.

Really?? So when an Amgen, a Pfizer, Merck, Genentech, Bristol Myers Squibb, invest money into a company to collaborate in a trial to pump up their pipeline, did they discover the drug, or did they BUY a share of it
with their capital and clinical expertise. You come here looking to say that
I said that PPHM has discovered the 3G4, Tarvacin platform. I have said and posted all over this board that Drs. Thorpe and Shan discovered Tarvacin and that a Nobel prize could be in store for Dr. Thorpe. Show me where I said PPHM discovered the drug! If you are going present your case, show the proof. You only come here to trying to missinform others through your agenda that has no purpose other than to waste space and start trouble. Sad for you.......

[Preciouslife1]

Here is a great picture provided by jazzbeerman on the other IHUB site. The green is Tarvacin binding to the tumor cells. It's like Pacman game of old where it enters the cell and starts surrounding and gobbling. It alerts the macrophage to attack the virus, infected cell, or cancer cell Great Picture of Tarvacin IMO. Had to repost it so that anone coming here will see it on this page too..

[Preciouslife1]

H5N1 is spreading through Turkey and Russia and Iran have closed borders with Turkey. This is no joke and the WHO in not wanting to start a panic is keeping hush hush....
H5N1 has shown signs of rapidly evolving in the Volga Delta and Crimea Peninsula to the north of the current outbreaks in Turkey. However, birds are now migrating to the south through the Middle East and into Africa, so more spread of H5N1 into new regions is a virtual certainty.
If the H5N1 infected migrating birds can readily transmit H5N1 to humans, as suggested by the six hospitalized case, then a dramatic up-tick in human cases would be expected.
H5N1 in wild birds can recombine with H9N2 which is endemic in the Middle East to acquire the HA S227N polymorphism, which has increased affinity for human receptors which would increase transmission efficiencies to humans. Moreover, all H5N1 wild bird sequences published since the May, 2005 Qinghai Lake outbreak have had the human PB2 E627K which is linked to increased virulence in mammals and the change allows H5N1 to grow more efficiently at lower body temperatures of mammals, which is lower than cold blooded avian species.
These molecular changes could dramatically increase the efficiency of human-to-human H5N1 transmission and are cause for considerable concern.

[SSHGuru]

You don't need to own the patents to enter into exclusive agreements to use them.

Get a clue. You have no reason to be here other than bash.

Why don't you register with a real name. I'll suggest one if you want.

Scott Weiner
Attorney at Law

Originally Posted by Unregistered

"Peregrine Pharmaceuticals is developing a version of 3G4 called Tarvacin for cancer treatment and recently received approval from the Food and Drug Administration for a phase I clinical trial. The compound was discovered by Dr. Thorpe's lab, and Peregrine has a sponsored research agreement with UT Southwestern to further develop the drug."

That's what I said.

You claimed that Peregrine OWNS the tech. They do not.

Call Peregrine Investor Relations. Ask if they OWN those patents you claimed they own. They will tell you they do not own them. Because they don't.

Real biotech's (and real companies) actually own what they're selling/developing.

Duh.

"You don't need to own the patents to enter into exclusive agreements to use them."

I never said what you said I said. You seem to have subpar reading comprehension.

"Why don't you register with a real name."

I didn't want to take the time to do it. Why does it matter?

"Scott Weiner Attorney at Law"

Odd, for some reason you felt the need to make it publically known that you are an attorney, or at least play one on the internet. Why is that? By all appearances you appear to be more of an ordinary internet spammer for a lame penny stock pumping website.

Your website contact info indicates it's located in Florida, but there's no licensed attorney in Florida for a Scott Weiner. Why would that be?

http://www.floridabar.org/names.nsf/...DB=name s.nsf

Domain name: SSHGURU.COM

Registrant Contact:
SSHGuru
Scott Weiner (Scott@SSHGuru.com)
+1.9542247201
Fax: +1.9543372927
757 SE 17th Street
#1012
Fort Lauderdale, FL 33316
US

Administrative Contact:
SSHGuru
Scott Weiner (Scott@SSHGuru.com)
+1.9542247201
Fax: +1.9543372927
757 SE 17th Street
#1012
Fort Lauderdale, FL 33316
US

Technical Contact:
SSHGuru
Scott Weiner (Scott@SSHGuru.com)
+1.9542247201
Fax: +1.9543372927
757 SE 17th Street
#1012
Fort Lauderdale, FL 33316
US

Status: Locked

Name Servers:
ns1.sophiosoft.com
ns2.sophiosoft.com

Creation date: 21 Jul 2004 18:13:41
Expiration date: 21 Jul 2010 18:13:41

[Preciouslife1]

There are questions we must ask ourselves as human beings as to what are the motives behind their actions. Why do we do and say the things that we do? Is it out of Love or Fear. Anything not done out of Love is done out of some Fear. Fear of success, fear of failure, fear of intimacy, fear of so many things it would take forever here to list. So why are you here in a remote website where there are no bashers, except now for you.
What is the motive behind your actions? Is it hate? Do you hate me or what I post? Hatred stems from fear too. You have come to a board that is not like yahoo or Raging Bull where a diverse set of posters come some wanting to inform, some wanting to ask questions, some to bash others and some to just socialize with other posters. This is a site where current news and PR's on PPHM and the H5N1 Avian Flu get posted to inform others of what is transpiring within each realm. The positive private messages that I recieve only vindicates why I put so much time and effort here to try to inform others about a drug platform that is unrivaled in it's breadth and diversity and the potential for it to spin off a plethora of blockbuster treatments from a myriad of indications in cancer, anti viral and bio defense applications. I ask that you cease and desist from your actions here as the Yahoo and RB boards are wide open for you to conduct your agenda which if I think you have already been doing. No names, just do it there as this is a site run by very nice people whom have allowed me to use their forum to get the word out on Tarvacin and the Avian Flu. Now it is up to you to consider your actions and whom it could be affecting and impacting...PL1

Are you gay?

You are impossible to argue with in a logical manner because you do not think clearly.....

Example:

I say this: "You post like a nutcase on every board in the universe trying to encourage others to invest money on this company for science they don't even own."

Then you reply with this- "I have NEVER asked or told anyone to buy shares in PPHM or any other company. That is a bold faced lie."

You misquote me and then argue with yourself and then conclude I'm a liar based on your own statement.

You've got a lot of nerve! Misleading your flock and then failing to acknowledge it. Then you ask ME to stop posting here.

"Now it is up to you to consider your actions and whom it could be affecting and impacting".

I think YOU ought to consider your own actions and whom it could be affecting and impacting. This company is a shell and you are shamelessly pumping it only because your own a large number of shares. You've sold your soul for greed.

You're as bad as that 'Guru' guy pretending to be an attorney in an apparent attempt to silence me through intimidation.

Losers both of you!